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Abstract
Introduction. The aim of this study was to evaluate the effectiveness of the endovascular 
treatment of atherosclerotic stenosis/occlusion of the popliteal artery according to TASC II rec-
ommendat ions us ing the Jaguar SM sel f-expanding stent depending on the modi f iable 
 and unmodifiable risk factors of repeated stenosis/occlusions.
Material and methods. The study included 126 men and 46 women aged 46–95 years in 2011–2015. 
Surgeries were performed in the scheduled and emergency mode. Angioplasty of the popliteal artery with 
the Jaguar stent implantation was performed in patients with severe chronic limb ischaemia and critical limb 
ischaemia. Post-operative popliteal artery patency was evaluated in relation to sex, obesity, diabetes, smoking 
tobacco, and patency of the lower extremity arteries.
Results. The postoperative patient follow-up was conducted for 60 months, demonstrating 67% patency after 
12 months, 59% patency after 24 months, 53% patency after 36 months, 45% patency after 48 months, 
and 31% patency after 60 months.
Conclusions. The Jaguar™ stent implantation is an effective and safe method of treatment of atherosclerotic 
stenosis and occlusion of the popliteal artery. The occlusion was found in patients with the risk factors such as: 
obesity, diabetes, and tobacco smoking, limited runoff arteries in the lower leg. Stent fracture did not occur in 
any patient. 
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Introduction
The popliteal artery is one of the most movable 
arteries. Treatment of atherosclerotic lesions in the 
popliteal artery near the knee joint poses a challenge for 
the endovascular treatment due to the biomechanical 
processes taking place in this area. The morphology of 
the popliteal artery changes as the knee joint moves. 
Rotational, tensile, and compressive forces acting simul-
taneously on the artery and the stent have a negative 
effect on the results of endovascular procedures. For 
many years the lesions in this area have been surgical-
ly treated most frequently using the saphenous vein. 
Nowadays, with the development and improvement 
of endovascular materials, the number of minimally 
invasive procedures in this area has increased signif-
icantly. A normal balloon angioplasty or a mechanical 
atherectomy are the preferred methods of treatment 
in case of atherosclerotic lesions in the popliteal artery 
[1]. When the efficacy of these techniques is insufficient, 
the stent implantation is necessary [2, 3].
The first results from the implantation of steel stents 
to the popliteal artery were unsatisfactory (due to the 
inadequate physical properties of the material in trou-
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blesome anatomical and functional locations). Slightly 
better results were achieved using nitinol stents. How-
ever, there have always been concerns about potential 
stent breakage and subsequent restenosis.
Nowadays, stents are more often implanted after 
angioplasty, because there is not only an assumption, 
but also numerous comments and scientific publications 
confirming that the better production technology, 
efficiency, and physical structure of the new stents 
is applicable in these anatomic locations. This idea is 
supported by numerous publications [4, 5].
Material and methods
The aim of this study was to retrospectively analyse 
the efficacy and durability of endovascular angioplasty 
of stenosis and occlusions of the popliteal artery using 
the Jaguar stent.
The study included 126 men and 46 women, a total 
of 172 patients treated in 2011–2015. Surgeries were 
performed in the scheduled and emergency mode. 
The age range of these patients was between 46 and 
95 years. Atherosclerosis was the causative factor in 
case of all the arterial lesions. Smokers accounted for 
25.5% of all patients, obesity was found in 31.5%, 
diabetes in 24.5%, while 48% of patients were treat-
ed due to arterial hypertension, connective tissue 
diseases, and hyperlipidaemia. The patients qualified 
for the surgery included those with severe ischaemic 
symptoms of lower extremities (claudication distance 
less than 100 m), and with symptoms of critical limb 
ischemia (pain during rest, ulcerations, necrosis). The 
patients were prepared for the surgeries in a typical 
way. After the arteriography was performed, the 
balloon angioplasty was performed first. The stent 
was implanted in case of ineffective artery dissection, 
atherosclerotic plaque detachment or separation, and 
in case of restenosis after previous intervention. Each 
stent was post-dilated with a balloon. After the proce-
dure, patients received a double antiplatelet therapy 
and low molecular weight heparin in a prophylactic 
dose. On the first post-op day they were discharged 
home, with further treatment and follow-up continued 
in outpatient basis. The effectiveness of the treatment 
was evaluated in 12-month, 2-year, 3-year, 4-year and 
5-year follow-ups.
Results
Long-term patency of the popliteal artery after the 
Jaguar™ stent implantation is shown on the KM curve 
(Fig. 1).
In the specific years of follow-up, it is presented 
as follows.
Figure 1. Observation of the five-year patency of the popliteal 
artery — a summary chart. Patience and sex
Figure 2. PA Patency after 12 months
Figure 3. PA Patency after 24 months
During 12-month follow-up, the patency of the 
popliteal artery was maintained in 115 patients, i.e. 
67% (Fig. 2). 
During the 24-month follow-up, the patency of 
the popliteal artery was maintained in 102 patients, 
i.e. 59% (Fig. 3).
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During the 36-month follow-up, the patency of the 
popliteal artery was maintained in 54 patients (102 
patients in 3-year follow-up), i.e. 53% (Fig. 4).
During the 48-month follow-up, the patency of 
the popliteal artery was maintained in 26 patients (58 
patients in the 4-year follow-up), i.e. 45% (Fig. 5).
During the 60-month follow-up, the patency of the 
popliteal artery was maintained in 5 patients (16 patients 
in the 5-year follow-up), i.e. 31% (Fig. 6).
Patients who experienced stent occlusion after 
the implantation were evaluated for the presence of 
all known risk factors such as obesity, diabetes, and 
smoking. This is shown in the KM figures (Figures 7–9).
In the long-term follow-up the patency of the ar-
teries below the knee — a condition of the so-called 
good runoff — is an important factor that provides good 
results after the stent implantation into the popliteal 
artery (Fig. 10).
Discussion
The advantages of the endovascular treatment of 
stenosis/obstructions did not raise any doubts in the 
Figure 4. PA Patency after 36 months
Figure 5. PA Patency after 48 months
Figure 6. PA Patency after 60 months
Figure 7. Patency of the popliteal artery after stent implanta-
tion and the occurrence of obesity
Figure 8. Patency of the popliteal artery after stent implanta-
tion and the occurrence of diabetes mellitus
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global indications. However, is the use of the self- 
-expandable stent in the popliteal segment the best 
solution? What can we say today?
Over the years, the preferred treatment method of 
occlusions in the femoro-popliteal segment from the 
adductor’s canal to the anterior tibial artery origin was 
the femoropopliteal bypass from the patient’s own vein 
or using a vascular prosthesis [6–8]. However, despite 
the effectiveness of this method, complications associat-
ed with this surgical technique occurred in patients [9].
The endovascular therapy is currently the most 
commonly used method of treatment in case of the 
peripheral artery lesions. RESILIENT2 — the first 
large randomized study — showed good results of 
the endovascular treatment in changes in the femoral 
and popliteal segment. [11, 13]. Currently, there are 
guidelines of the European Society of Cardiology (ESC 
2017, Europe)/European Society for Vascular Surgery 
(ESVS 2017, Europe), Chirurgia Polska (2009, Polska) 
confirming the effectiveness of this method in the 
treatment of atherosclerotic lesions in the peripheral 
arteries of the lower extremities [10, 11]. 
Atherosclerotic lesions in peripheral arteries grow 
for years. The nature of these lesions is usually mul-
tifocal and varied (stenoses and occlusions). Having 
considered the foregoing in the initial recommendations 
the patients with advanced lesions (TASC C and D) 
should be disqualified from endovascular treatment. 
At the moment, based on numerous scientific studies, 
patients with very advanced atherosclerotic lesions are 
suggested to be treated by means of endovascular pro-
cedure [12]. Although we achieve worse results in the 
long-term observations, this treatment allows healing 
of ischaemic ulcers and may prevent early amputation. 
It also does not interfere with the implementation of 
the femoropopliteal bypass which can be implanted 
below the implanted stent [14, 15].
Whether the stent implantation provides better 
results compared to the angioplasty without the stent 
implantation, it still raises a lot of controversies. Among 
other things, in their meta-analysis, Balk et al. did not 
find any significant differences in clinical results, includ-
ing repeated intervention, amputation, mortality, and 
frequency of complications between patients undergo-
ing balloon angioplasty (PTA) alone and stenting.
Recent studies, however, demonstrate better results 
and greater efficacy after the stent implantation. In 
a recent meta-analysis including a total of 40 rand-
omized studies, Simpson et al. e.g. proved that the im-
plantation of self-expanding stents significantly reduces 
recurrent stenoses and occlusions when compared to 
the angioplasty without the stent implantation.
The second stage of the study (RESILIENT2) [10] 
comparing the stent and balloon angioplasty implanta-
tion in the femoropopliteal segment showed greater 
efficacy after the stent implantation compared to 
the balloon angioplasty alone. 80% patency after 
the stent deployment and 38% patency after the 
angioplasty alone were achieved in the 12-month 
follow-up [13].
The selection of the stent depends on many factors: 
diameter, length, elasticity, and susceptibility to frac-
tures. Modern Nitinol® Jaguar™ braided stent presents 
good biocompatibility. It is made without welding or 
soldering and is resistant to corrosion. This stent per-
fectly adapts to the curvature of the vessel and adheres 
to the artery wall. It is radiologically visible with all its 
markers, providing the ability to manipulate the stent 
Figure 9. Patency of the popliteal artery after stent implanta-
tion and smoking
Figure 10. Patency of the popliteal artery after the stent 
implantation and the amount of expensive arteries of the shin
84
Acta Angiol, 2018, Vol. 24, No. 3
www.journals.viamedica.pl/acta_angiologica
inside the vessel even after a partial deployment. It also 
has a system to prevent migration [16].
Our results with the Jaguar™ stent are comparable 
to the results of other authors using other nitinol stents 
in this area, confirming that Jaguar™ self-expanding 
stent meets the expectations and clinical demands 
associated with it [17–19].
Restenosis is one of the most important problems 
in the endovascular surgery. The increase in the thick-
ness of the intima-media complex as a response to 
trauma, such as PTA or the stent implantation, is one 
of the factors leading to stenosis recurrence. Searches 
for new endovascular treatment equipment have led 
to the production of drug-eluting balloons and stents, 
with the aim of stopping the hypertrophy of the intima. 
After the assessment of several years of follow-ups, 
the effectiveness of this method is comparable to the 
traditional one [20–23].
Percutaneous atherectomy is another method of 
restoring the flow in the occluded segments of the 
popliteal artery. So far, however, atherectomy has not 
been widely used due to a significant percentage of 
restenosis [24, 25].
Conclusions
The Jaguar stent implantation is an effective and safe 
method of treatment in the atherosclerotic stenosis and 
occlusion of the popliteal artery.
1. In the 1-year follow-up, only less than 1/3 of patients 
experienced an occlusion.
2. Stent fracture did not occur in any patient.
3. The number of patent below the knee arteries is 
an important factor in maintaining patency of the 
popliteal artery after the stent implantation. 
4. The metabolic syndrome is an important factor 
causing recurring occlusion of the popliteal artery 
after the stent implantation.
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